MapLight Therapeutics raised USD 225 million in a Series C funding round led by Novo Holdings, with participation from new investors, including 5AM Ventures and Cowen Healthcare Investments. This brings the company's total funding to USD to USD 268.1 million.
The funds are expected to be used for the development of ML-007C-MA, MapLight's novel therapeutic candidate, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis, set for 2024, and to bolster the company's other pipeline programs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.